Assenagon Asset Management S.A. lessened its stake in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Free Report) by 16.5% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 848,632 shares of the company’s stock after selling 167,447 shares during the period. Assenagon Asset Management S.A. owned 1.12% of Deciphera Pharmaceuticals worth $13,111,000 at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. Tudor Investment Corp Et Al acquired a new position in shares of Deciphera Pharmaceuticals during the 3rd quarter valued at $614,000. ExodusPoint Capital Management LP lifted its position in shares of Deciphera Pharmaceuticals by 87.6% during the 4th quarter. ExodusPoint Capital Management LP now owns 579,654 shares of the company’s stock valued at $9,501,000 after acquiring an additional 270,685 shares during the period. Russell Investments Group Ltd. raised its holdings in Deciphera Pharmaceuticals by 4.2% during the fourth quarter. Russell Investments Group Ltd. now owns 94,568 shares of the company’s stock worth $1,550,000 after buying an additional 3,814 shares during the last quarter. Armistice Capital LLC raised its holdings in Deciphera Pharmaceuticals by 8.5% during the fourth quarter. Armistice Capital LLC now owns 5,172,000 shares of the company’s stock worth $84,769,000 after buying an additional 404,000 shares during the last quarter. Finally, Braidwell LP acquired a new position in Deciphera Pharmaceuticals during the fourth quarter worth $53,620,000. Institutional investors and hedge funds own 79.09% of the company’s stock.
Deciphera Pharmaceuticals Price Performance
NASDAQ DCPH opened at $14.08 on Friday. Deciphera Pharmaceuticals, Inc. has a 1 year low of $12.14 and a 1 year high of $22.76. The firm has a market cap of $1.11 billion, a price-to-earnings ratio of -5.99 and a beta of 0.67. The company has a fifty day moving average price of $14.12 and a 200-day moving average price of $15.54.
Analyst Ratings Changes
Several research analysts have weighed in on DCPH shares. JMP Securities restated a “market outperform” rating and set a $23.00 price objective on shares of Deciphera Pharmaceuticals in a report on Wednesday, March 15th. Stifel Nicolaus lowered their price objective on shares of Deciphera Pharmaceuticals from $17.00 to $14.00 in a report on Thursday, May 4th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Deciphera Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $21.78.
Insider Activity at Deciphera Pharmaceuticals
In related news, Director Franklin Stuart Friedman purchased 10,000 shares of Deciphera Pharmaceuticals stock in a transaction that occurred on Thursday, June 8th. The stock was bought at an average price of $13.88 per share, for a total transaction of $138,800.00. Following the completion of the transaction, the director now owns 10,000 shares in the company, valued at $138,800. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Deciphera Pharmaceuticals news, Director Franklin Stuart Friedman bought 10,000 shares of the business’s stock in a transaction on Thursday, June 8th. The stock was purchased at an average price of $13.88 per share, for a total transaction of $138,800.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at $138,800. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Dennis Leo Walsh bought 11,000 shares of the business’s stock in a transaction on Wednesday, May 10th. The shares were acquired at an average price of $13.86 per share, with a total value of $152,460.00. Following the transaction, the director now directly owns 11,000 shares of the company’s stock, valued at $152,460. The disclosure for this purchase can be found here. 4.43% of the stock is owned by company insiders.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovering, developing, and commercializing medicines to improve the lives of cancer patients in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.
Recommended Stories
- Five stocks we like better than Deciphera Pharmaceuticals
- Tesla: Can Downgrades Make Sense After A 170% Rally?
- Buffett’s Berkshire Increases Stake In Occidental Petroleum (OXY)
- Rally Gains Momentum On Soft PCE Data
- Bank of America, JPMorgan, Goldman Sachs Set For Dividend Growth?
- SMART Global Holdings Momentum, Room To Move Higher?
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
